Regenerative medicine replacing, engineering, or regenerating human or animal cells, tissues, or organs to restore or establish normal function. The regenerative medicine for cartilage consists of sales of entities (organizations, sole traders, and partnerships) that can grow muscles and organs in the lab and safely implant them when the body is unable to regenerate itself after injury or wear.
The major types of cartilage regenerative medicines are cell-based and non-cell-based. The type of treatment includes palliative and intrinsic repair stimulus. The regenerative medicine for cartilage is used for the repair and regeneration of hyaline cartilage, elastic cartilage, and fibrous cartilage. Modern cartilage regeneration methods include autologous chondrocyte implantation (ACI), autologous matrix-induced chondrogenesis (AMIC), and matrix-associated autologous chondrocyte implantation (MACI).
COVID-19 Impact analysis
The COVID-19 impacted the global regenerative medicine for cartilage market in the initial phase pandemic. Elective surgeries are being canceled or postponed to reserve the available limited capacities and resources such as hospital beds and healthcare professionals toward COVID-19 patient care. Moreover, to control the rising number of positive COVID-19 cases, several countries have implemented lockdowns and curfews. Furthermore, patients are unable to visit hospitals, clinics, or OPDs due to the lockdowns. The cartilage repair and regeneration industries are projected to be hindered by the temporary denial of wound care services, cancer care surgeries/therapies, and other healthcare services.
Top Impacting Factors
- Increasing geriatric population generating incidences of articular damage in knees will propel the regenerative medicine for cartilage market.
- Emerging clinical trials and the development of new technologies (stem cells, gene therapy, tissue engineering, and cartilage restoration technologies) that transform the cartilage regeneration market are thriving the market growth.
- Additionally, factors such as the rising government investments in cartilage regeneration research, increasing number of companies making significant investments in R&D, resulting in a strong pipeline of products based on various approaches to cartilage repair are boosting the market growth.
- Moreover, growth factors in the form of platelet-rich plasma (PRP) therapy are injected to promote tissue regeneration effectively is also propelling the market.
- However, high cost of regenerative medicine therapies for the cartilage market hinders the growth of the market.
Market Trends
New product launches to flourish the market
In April 2019, Smith & Nephew Plc., a UK-based multinational medical equipment manufacturing company, acquired Osiris Therapeutics, Inc. for approximately $660 million. The acquisition is expected to stimulate growth from Smith & Nephew's advanced wound management franchise. Osiris Therapeutics, Inc. is a US-based company that researches and develops therapeutic products for the regeneration of human connective tissues.
In 2019, MEDIPOST (South Korea) expanded the GMP manufacturing facility to accelerate CARTISTEM production.
In 2018, Vericel Corporation collaborated with Innovative Cellular Therapeutics (ICT, China), under this collaboration, ICT will develop and distribute MACI, Epicel, Ixmyelocel-T, and Carticel products in China, South Korea, Singapore, and other countries in Asia.
Surge in incidence of osteoarthritis
The growing incidence of osteoarthritis across the globe will surge the market growth for regenerative medicine for cartilage. Osteoarthritis is a degenerative joint disorder that generally attacks the articular cartilage.
According to the Arthritis Foundation (2019), degenerative joint illnesses such as osteoarthritis will affect at least 130 million people worldwide by 2050. Autologous chondrocyte implantation and scaffold implants are two of the most common treatments for osteoarthritis. Thus, the increasing incidence of osteoarthritis is expected to drive the demand for regenerative medicine for the cartilage market.
Key Benefits of the Report
- This study presents the analytical depiction of the regenerative medicine for cartilage along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the regenerative medicine for cartilage market share.
- The current market is quantitatively analyzed to highlight the regenerative medicine for cartilage market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed regenerative medicine for cartilage market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Regenerative Medicine for Cartilage Report
- Who are the leading market players active in the regenerative medicine for cartilage market?
- What current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What future projections would help in taking further strategic steps?
- What is "regenerative medicine for cartilage "?
- What is "regenerative medicine for cartilage " market prediction in the future?
- Who are the leading global players in the "regenerative medicine for cartilage " market?
- What are the current trends and predicted trends?
- What are the key benefits of the "regenerative medicine for cartilage " market report?
Regenerative Medicine for Cartilage Market Report Highlights
| Aspects | Details |
 By Treatment Modality |
|
 By Treatment Type |
|
 By Site |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Stryker Corporation, Vericel Corporation, B. Braun Melsungen AG, CellGenix, Collagen Solutions PLC, Arthrex Inc., CONMED Corporation, Smith and Nephew plc, BioTissue Technologies, Zimmer Biomet Holdings Inc. |
Loading Table Of Content...
